Kenvue (KVUE) is trading lower as the market revisits headline and court-related overhangs around Tylenol (acetaminophen) and allegations that prenatal exposure is linked to autism/ADHD, a risk that can pressure valuation through potential settlements, labeling changes, and brand-demand uncertainty. A recent escalation point has been a state-level action in Texas alleging the companies withheld evidence about these risks, keeping the issue front-and-center for investors.

Even without a fresh earnings release, KVUE has become highly sensitive to incremental litigation/regulatory signals because Tylenol sits within Kenvue’s self-care portfolio and is viewed as a meaningful profit contributor. When that risk premium rises, the stock can gap lower quickly as investors model higher legal expense, potential adverse rulings, and reputational damage that could weigh on volumes and pricing power.

KVUE is also trading in the shadow of Kimberly-Clark’s agreed acquisition of Kenvue, which is expected to close in the second half of 2026. On days when uncertainty rises—whether from litigation headlines, timing questions, or broader risk-off tape—merger-arbitrage positioning can magnify downside as the perceived probability-weighted value of the takeout narrows.